HC Wainwright Boosts Replimune Group (NASDAQ:REPL) Price Target to $21.00

Replimune Group (NASDAQ:REPL) had its target price raised by analysts at HC Wainwright from $17.00 to $21.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 52.73% from the stock’s previous close.

REPL has been the subject of a number of other reports. BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $19.14.

Replimune Group Stock Up 5.6 %

Shares of NASDAQ REPL opened at $13.75 on Wednesday. The stock has a fifty day moving average price of $12.18 and a 200 day moving average price of $11.28. The company has a market cap of $940.78 million, a P/E ratio of -4.51 and a beta of 1.28. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Research analysts anticipate that Replimune Group will post -2.91 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP raised its stake in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP raised its stake in shares of Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. State Street Corp lifted its holdings in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Finally, Geode Capital Management LLC grew its position in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.